Dermata initially launched with a drug product being developed to treat the inflammation and erythema of rosacea. However, as we continued to work with our partner to explore our product’s effect on multiple inflammatory pathways, we recognized that we could leverage this compound by developing it for other dermatologic and ophthalmic diseases being treated by dermatologist. Many of these diseases have a similar pathophysiology as rosacea, leading us to believe they may respond to our current drug formulation.
This strategic adjustment was only made possible by the innovative and out of the box thinking of our team working in collaboration with our partner. Our diverse and passionate team has many years of experience in developing and commercializing pharmaceutical products in the US and worldwide. We have a proven track record of growing small pharmaceutical companies into multi-product, multi-billion dollar companies with international presence, while still maintaining small company values. As we progress, we will continue to focus on utilizing our knowledge and expertise to develop differentiated products for dermatology patients.